Clinical trial
Study Evaluating Orally Administered ERB-041 in Subjects With Active…
NCT00275379 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Withdrawn
Key facts
| NCT number | NCT00275379 |
|---|---|
| Title | Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Exploratory Study of Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | Cystitis, Interstitial |
| Intervention type | Drug |
| Interventions | ERB-041 |
| Enrollment | 0 |
| Start date | Aug 1, 2006 |
| First posted | Jan 11, 2006 |
| Last update posted | Oct 1, 2020 |
| Countries | Austria, Germany, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: